

Minutes of Board of Directors meeting

For Minapharm Pharmaceuticals and Chemical Industries S.A.E

financials Q2/2023 approval

On 13/8/2023 AT THREE OCLOCK the Board of Directors of Minapharm Pharmaceuticals and Chemical Industries S.A.E held at the company headquarter in the following address:

(The third industrial zone A2- 10th of Ramadan city - ElSharqiyah Governorate).

meeting is driven by Dr. Wafik ElBardissi, Chairman and CEO of the company.

Attendees:

- **Dr. Amr Mohamed Sobhy Hamza Elshabrawishi** - Deputy Chairman of the Board of Directors.
- Dr. Anwar Mikhail Member of the Board
- **Dr. Shaheer Wafik ElBardissi – Executive Board Member**
- **Mr. Albert Samy** - Secretary of the Meeting.

Agenda:

1. Review the financial statements of the company for the period ending at 30-6-2023
2. Approve the company financial statements At 30/6/2023
3. New risen subject.

1- Review the financial statements of the company for the period ending 30/6/2023

Net sales on 30/6/2023 1.251 M compared to 1.104 M on 30/6/2022 with an increase of 147.00 M with 13.31% percentage.

Net profit after taxes on 30/6/2023 77.48 M compared to 145.52 M on 30/6/2022 an decrease of 68.04 M .

2- Company financial statements approval on 30/6/2023

شركة مينافارم للأدوية والمستحضرات الكيميائية
أط. ش. البرديسي من أسماء فهمي
خاض الرقابة الإدارية - أرض الجوزلف

After the members of the Board of Directors reviewed and discussed the financials of the company for the period ending 30/6/2023 without any observations, decision is to approve the company's financials on 30/6/2023

3- New raised subject.

No other subject is risen

The Chairman of the Board of Directors thanked the attendees, meeting concluded at four oclock

Commitment

The Company undertakes that the Board of Directors held on 13/8/2023 Minapharm Pharmaceutical and Chemical Industries shall include all major events that must be disclosed according to stock market Laws and applicable Regulation, Rules and Decisions Governing.

Chairman and CEO

Dr. Wafik ElBardissi

Wafik ElBardissi

شركة مينافارم للأدوية والصناعات الكيماوية
أط ش. البرديسي من أسماء فهمي
مكتب الرقابة الإدارية - أرض الجسر

Company name: Minapharm pharmaceutical

an audited financial indicator for the financial year period ended on 30/06/2023.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

First, the financial indicators

(A) statement of profit or loss for the year/period ended in 30/06/2023

	Current period	comparative financial statements	change%
Revenue/sales	1,251,100,448	1,104,118,870	13%
Total profit (loss)	416,118,978	352,014,200	18%
The ratio of total profit to revenue/sales	٣٣%	٣٢%	4%
Net profit (loss) before tax from continuing activities	105,697,127	189,171,287	-44%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	77,484,708	145,528,943	-47%
Earnings I (losses) per share (EPS)	6	11	-48%
Diluted share of profit I loss (if any)	-	-	0%

شركة مينافارم للأدوية والمستحضرات الكيميائية
أط. ش. البرديس من أسماء فهمى
مخلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet www.minapharm.com

(B) Statement of financial position in 30/06/2023

	Current period	comparative financial year (previous Year)	change%
Net working capital	(394,032,711)	129,580,072	-404%
Owner's equity	1,050,441,520	1,028,693,497	2%
Paid capital	122,934,400	122,934,400	0%
Reserves	291,996,136	291,996,136	0%
Retained earnings	627,652,811	537,860,553	17%
The profit (loss) of the period	77,484,708	145,528,943	-47%
Other			
Treasury Shares	69,626,535	69,626,535	0%

(C) cash flow statement for the year 30/06/2023

	Current period	comparative financial statements	Change%
Cash flows from (to) operating activities	244,347,034	33,135,845	637%
Cash flows from (to) investment activities	(736,111,431)	(367,746,936)	100%
Cash flows from (to) financing activities	710,548,536	390,981,443	82%

Second: Material events that have occurred since the date of the financial results till now and should be disclosed.

None

شركة مينافارم للأدوية والصناعات الكيماوية
أحد شركات المجموعة من أسماء قهسي
القاهرة - مصر - الجسر

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Agree


We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 13/8/2023 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .

Investor relations officer



Date 13 / 8 / 2023

Chairman



شركة مينافارم للأدوية والصناعات الكيماوية
أصل ش. البروتيبس من أسماء فهمي
مخاض الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet www.minapharm.com